Page 400 - 2014 Printable Abstract Book
P. 400
concordance for blinded quality control duplicates was 99.9%. Based on detailed medical record
abstraction, we reconstructed radiation doses across the body and quantified cumulative exposure to
specific chemotherapeutic agents. A total of 879 survivors developed one or more subsequent neoplasms
during follow-up, including basal cell carcinoma of the skin (N=362 survivors), breast cancer (N=178),
meningioma (N=125), thyroid cancer (N=90), and sarcoma (N=58). Ongoing analyses are investigating
associations between each locus and each subsequent neoplasm type, considering genotypes either as
independent contributors to risk or as potential modifiers of radiation- or chemotherapy-related risks.
Results from the study should further our understanding of cancer susceptibility and the etiology of
multiple primary cancers in childhood cancer survivors, as well as elucidate potential mechanisms of
radiation- and chemotherapy-related carcinogenesis. In addition, identification of patients with genetic
susceptibility to subsequent neoplasms may impact clinical decision-making for childhood cancer
treatments and/or follow-up care.
SNF. BRIDGING MECHANISMS OF RADIATION ACTION AT LOW DOES AND HUMAN RISK: JOINT
EU/DoReMi AND US NCRP SESSION
Uncertainties in low dose health risk assessment have been recognized as problematic for
regulatory policy and public communication by the Multidisciplinary European Low Dose Initiative
(MELODI, www.melodi-online.eu) as well the US NCRP (Report 171). Both organizations have also
considered ways to scientifically address these issues and strengthen the knowledge basis of risk
assessment. MELODI is now an association consisting of more than 30 European radiation protection
authorities, research centers and funding bodies that share an interest in low dose risk research. The
European Network of Excellence on low dose risk (DoReMi, 2010-2015) is one of the efforts conceived to
advance the scientific goals, by promoting and carrying out multidisciplinary research to investigate low
dose risk. The research program addresses the shape of the dose response for cancer, individual
susceptibility, and non-cancer effects. A way forward proposed by the NCRP recommends not only
additional epidemiological studies but also development of a means for more reliably combining the
epidemiology data with experimental laboratory animal and cellular data. Such an approach can enhance
the overall risk assessment objective by providing biologically refined data to strengthen the estimation
of effects at low doses as opposed to sole use of mathematical models of epidemiological data that are
primarily driven by medium/high doses (in a range greater than 100 mSv). The session provides a forum
for global discussion on the roles of radiation biology and epidemiology in low dose risk assessment. The
session includes presentations that discuss the applicability of various biomarkers (of exposure, effect,
susceptibility, risk, disease etc.) for molecular epidemiological studies of radiation-exposed populations
as well as examples of epidemiological data analyses with biologically-based models of carcinogenesis.The
DoReMi Network of Excellence has received funding from the European Atomic Energy Community's
Seventh Framework Programme (FP7/2007-2011) under grant agreement n° 249689.
abstraction, we reconstructed radiation doses across the body and quantified cumulative exposure to
specific chemotherapeutic agents. A total of 879 survivors developed one or more subsequent neoplasms
during follow-up, including basal cell carcinoma of the skin (N=362 survivors), breast cancer (N=178),
meningioma (N=125), thyroid cancer (N=90), and sarcoma (N=58). Ongoing analyses are investigating
associations between each locus and each subsequent neoplasm type, considering genotypes either as
independent contributors to risk or as potential modifiers of radiation- or chemotherapy-related risks.
Results from the study should further our understanding of cancer susceptibility and the etiology of
multiple primary cancers in childhood cancer survivors, as well as elucidate potential mechanisms of
radiation- and chemotherapy-related carcinogenesis. In addition, identification of patients with genetic
susceptibility to subsequent neoplasms may impact clinical decision-making for childhood cancer
treatments and/or follow-up care.
SNF. BRIDGING MECHANISMS OF RADIATION ACTION AT LOW DOES AND HUMAN RISK: JOINT
EU/DoReMi AND US NCRP SESSION
Uncertainties in low dose health risk assessment have been recognized as problematic for
regulatory policy and public communication by the Multidisciplinary European Low Dose Initiative
(MELODI, www.melodi-online.eu) as well the US NCRP (Report 171). Both organizations have also
considered ways to scientifically address these issues and strengthen the knowledge basis of risk
assessment. MELODI is now an association consisting of more than 30 European radiation protection
authorities, research centers and funding bodies that share an interest in low dose risk research. The
European Network of Excellence on low dose risk (DoReMi, 2010-2015) is one of the efforts conceived to
advance the scientific goals, by promoting and carrying out multidisciplinary research to investigate low
dose risk. The research program addresses the shape of the dose response for cancer, individual
susceptibility, and non-cancer effects. A way forward proposed by the NCRP recommends not only
additional epidemiological studies but also development of a means for more reliably combining the
epidemiology data with experimental laboratory animal and cellular data. Such an approach can enhance
the overall risk assessment objective by providing biologically refined data to strengthen the estimation
of effects at low doses as opposed to sole use of mathematical models of epidemiological data that are
primarily driven by medium/high doses (in a range greater than 100 mSv). The session provides a forum
for global discussion on the roles of radiation biology and epidemiology in low dose risk assessment. The
session includes presentations that discuss the applicability of various biomarkers (of exposure, effect,
susceptibility, risk, disease etc.) for molecular epidemiological studies of radiation-exposed populations
as well as examples of epidemiological data analyses with biologically-based models of carcinogenesis.The
DoReMi Network of Excellence has received funding from the European Atomic Energy Community's
Seventh Framework Programme (FP7/2007-2011) under grant agreement n° 249689.
